MD13
Based on 1 Customer Validation
MD13 is a MIF PROTAC degrader with a DC50 of approximately 100 nM. MD13 induces ubiquitination and degradation of MIF by recruiting the Cereblon Cullin RING E3 ubiquitin ligase complex. MD13 inactivates the MAPK pathway and induces G2/M phase cell cycle arrest. MD13 exhibits antiproliferative effects in 3D tumor spheroid models. MD13 can be used in lung cancer-related research.
(Pink: Macrophage migration inhibitory factor (MIF) Target protein ligand; Blue: Cereblon ligand (HY-10984); Black: linker).
For research use only. We do not sell to patients.
- Purity : 99.96%
- CAS No.: 2758431-97-7
- Formula: C35H35N5O8
- Molecular Weight:653.68
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
All PROTACs Isoforms
More
Biological Activity
Description
IC50 & Target
[1]|
Cereblon |
In Vitro
MD13 potently inhibits purified MIF tautomerase activity with a Ki of 71 nM[1].
MD13 (0.01-20 μM; 3-48 h) induces potent, time-dependent, cereblon- and proteasome-dependent MIF degradation in A549 cells, with a DC50 of ~100 nM and maximal degradation of 90-95%[1].
MD13 (0.01-20 μM; 72 h) dose-dependently inhibits 2D monolayer proliferation of A549 cells, achieving ~50% inhibition at 20 μM after 72 h[1].
MD13 (2 μM; 6-48 h) inhibits ERK phosphorylation in A549 cells, reducing pERK levels by ~50% at 2 μM after 24 h of treatment[1].
MD13 (1-5 μM; 48 h) dose-dependently induces G2/M phase cell cycle arrest in A549 cells, increasing the proportion of G2/M-phase cells to 23% at 5 μM after 48 h[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:A549 human lung adenocarcinoma cells
-
Concentration:0.01-20 μM (dose-response); 2 μM (time-course); 0.2-20 μM; 2 μM (with 2 μM Bortezomib co-treatment); 2 μM (with 50 μM MIF inhibitor 3 or 50 μM CRBN inhibitor 4 pretreatment)
-
Incubation Time:12 h (dose-response); 3-48 h (time-course); 12 h; co-treatment; 1 h pretreatment followed by MD13 treatment
-
Result:Induced dose-dependent MIF degradation, with a half-maximal degradation concentration (DC50) of ~100 nM (western blot) or ~200 nM (ELISA), and maximal degradation of 90-95% at concentrations >1 μM.
Showed a Hook effect at 20 μM.
Induced detectable degradation after 3 h of treatment with 2 μM MD13, reached >92% by 6 h, and showed only slight recovery after 48 h.
Had its MIF degradation effect rescued by co-treatment with Bortezomib, or pretreatment with MIF inhibitor 3 or CRBN inhibitor 4.
-
Cell Line:2D monolayer A549 human lung adenocarcinoma cells
-
Concentration:0.01-20 μM
-
Incubation Time:72 h
-
Result:Inhibited A549 cell proliferation in a dose-dependent manner, with the inhibitory effect visible at nanomolar concentrations and reaching ~50% inhibition at 20 μM.
Showed no significant inhibitory effect from inactive control compounds (MD15, MIF inhibitor 3, CRBN inhibitor 4) at concentrations up to 20 μM.
-
Cell Line:A549 human lung adenocarcinoma cells
-
Concentration:1-5 μM
-
Incubation Time:48 h
-
Result:Induced dose-dependent cell cycle arrest at the G2/M phase in A549 cells.
Increased the proportion of cells in G2/M phase from 12% (control) to 17%, 19%, and 23% with 1, 2, and 5 μM MD13 respectively.
Showed little to no effect on cell cycle distribution from inactive control compound MD15 at 5 μM.
-
Cell Line:A549 human lung adenocarcinoma cells
-
Concentration:2 μM
-
Incubation Time:6-48 h
-
Result:Inhibited ERK phosphorylation in A549 cells by ~50% after 24 h of treatment with 2 μM MD13, with the inhibition persisting at 48 h.
Showed no significant effect on pERK levels from inactive control compounds (MD15, MIF inhibitor 3, CRBN inhibitor 4).
Chemical Information
-
CAS No. 2758431-97-7
-
Appearance Solid
-
Molecular Weight 653.68
-
Formula C35H35N5O8
-
Color Light yellow to yellow
-
SMILES
O=C(NC1=CC=C(N2C(OC3=CC(O)=CC=C3C2)=O)C=C1)CCCCCCCNC4=CC=CC(C(N5C(CC6)C(NC6=O)=O)=O)=C4C5=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
In Vitro:
DMSO : 100 mg/mL (152.98 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocols
-
Multiplex immunofluorescence IHC
Multiplex immunofluorescence IHC detects multiple protein biomarkers in one tissue section by sequential antibody staining, HRP-mediated tyramide fluorophore deposition, heat-mediated antibody stripping, nuclear counterstaining, multispectral imaging, spectral unmixing, and digital cell phenotyping; TSA deposits fluorophore near the antigen so the fluorescence signal remains after primary and secondary antibodies are removed, enabling repeated staining cycles, including with antibodies from the same host species. Classic FFPE tumor immune-profiling applications use panels such as CD3, CD8, CD68/CD163, FOXP3, PD-1, PD-L1, pancytokeratin, Ki67, and DAPI to identify tumor cells, immune-cell subsets, checkpoint-marker expression, co-expression phenotypes, cell density, and spatial relationships in the tumor microenvironment.
-
Flow cytometric DNA-content cell-cycle staining
Flow cytometric DNA-content cell-cycle staining measures the fluorescence intensity of DNA-bound fluorochromes in single cells or nuclei to estimate DNA content distributions, allowing assignment of populations to G0/G1, S, and G2/M phases by DNA histogram deconvolution. Propidium iodide (PI) intercalates into DNA, and PI fluorescence is proportional to cellular DNA content when staining is performed under conditions that make DNA accessible and minimize non-DNA signal. Cells with G2/M DNA content are expected to show approximately twice the fluorescence intensity of G0/G1 cells, while S-phase cells occupy intermediate fluorescence values. PI-based DNA-content analysis can also detect cells with fractional DNA content, often reported as sub-G1, when DNA fragmentation and extraction during staining reduce retained DNA signal in apoptotic cells. DAPI is an alternative DNA fluorochrome for univariate DNA-content analysis, while bivariate approaches combining DNA content with proliferation
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
Multiplex immunohistochemistry
Multiplex immunohistochemistry (mIHC), also known as tyramide dignal amplification (TSA), is an enzymatic detection method that uses horseradish peroxidase (HRP) to perform high-density in-situ labeling of target proteins or nucleic acids.
-
Suspension Spheroid Formation (Low-Adhesion/Forced Aggregation)
Suspension spheroid formation by low-adhesion or forced aggregation is a scaffold-free 3D culture method in which cells are prevented from attaching to plastic and are guided to interact with each other, forming compact multicellular aggregates through cell-cell adhesion, gravity-driven settling, microwell confinement, or centrifugation-assisted aggregation. The method detects the capacity of a cell population to self-assemble into spheroids, and the main readouts are spheroid formation efficiency, morphology, compactness, projected area or diameter, circularity, viability, proliferation, and experimental responses such as drug sensitivity. Classic implementations include hanging drops, agarose or hydrogel microwells, ultra-low-attachment round-bottom wells, and centrifugation-assisted aggregation in non-adherent wells. Low-adhesion culture shifts the system away from cell-substrate adhesion and toward cell-cell adhesion, while round-bottom or microwell geometry concentrates cells into
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
-
Hanging Drop Spheroid Culture
Hanging drop spheroid culture is a scaffold-free 3D culture method in which a small droplet of cell suspension is inverted so that suspended cells sediment by gravity toward the lowest point of the drop, aggregate, and form a multicellular spheroid with direct cell-cell contact. Spheroids generated by this method are used to study 3D cell cohesion, cell-ECM interactions, drug response, co-culture organization, and tumor-like microenvironmental behavior. The primary readouts are spheroid formation efficiency, spheroid size, circularity or compactness, viability, and treatment response; these can be measured by bright-field microscopy, fluorescence viability staining, ATP-, fluorescence-, or colorimetric-based assays, and image-based diameter or volume calculations.
-
3D Tumor Spheroid Invasion Assay
3D tumor spheroid invasion assay measures outward tumor-cell movement from a compact multicellular spheroid into a surrounding extracellular matrix, producing image-based readouts such as invasion area, invasion distance, cell dispersion, or time-resolved cell movement. The method models tumor-cell interaction with matrix components in three dimensions and is used to study invasive phenotypes in cancer models including glioblastoma, squamous cell carcinoma, breast cancer, prostate cancer, ovarian cancer, and other solid tumor systems.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Purity & Documentation
-
Data Sheet (274 KB)
-
SDS (254 KB)
- English - EN (254 KB)
- Français - FR (254 KB)
- Deutsch - DE (254 KB)
- Norwegian - NO (254 KB)
- Español - ES (254 KB)
- Swedish - SV (254 KB)
- Italian - IT (254 KB)
- Korean - KR (254 KB)
- Portuguese - PT (254 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.5298 mL | 7.6490 mL | 15.2980 mL | 38.2450 mL |
| 5 mM | 0.3060 mL | 1.5298 mL | 3.0596 mL | 7.6490 mL | |
| 10 mM | 0.1530 mL | 0.7649 mL | 1.5298 mL | 3.8245 mL | |
| 15 mM | 0.1020 mL | 0.5099 mL | 1.0199 mL | 2.5497 mL | |
| 20 mM | 0.0765 mL | 0.3825 mL | 0.7649 mL | 1.9123 mL | |
| 25 mM | 0.0612 mL | 0.3060 mL | 0.6119 mL | 1.5298 mL | |
| 30 mM | 0.0510 mL | 0.2550 mL | 0.5099 mL | 1.2748 mL | |
| 40 mM | 0.0382 mL | 0.1912 mL | 0.3825 mL | 0.9561 mL | |
| 50 mM | 0.0306 mL | 0.1530 mL | 0.3060 mL | 0.7649 mL | |
| 60 mM | 0.0255 mL | 0.1275 mL | 0.2550 mL | 0.6374 mL | |
| 80 mM | 0.0191 mL | 0.0956 mL | 0.1912 mL | 0.4781 mL | |
| 100 mM | 0.0153 mL | 0.0765 mL | 0.1530 mL | 0.3825 mL |
Keywords
- MD13
- 2758431-97-7
- MD 13
- MD-13
- PROTACs
- Macrophage migration inhibitory factor (MIF)
- p38 MAPK
- cereblon Cullin RING E3 ubiquitin ligase complex
- MAPK pathway
- MIF
- Macrophage Migration Inhibitory Factor
- 3D tumor spheroid models
- HEK293 cells
- A549 cells
- G2/M cell cycle arrest
- ERK phosphorylation
- lung cancer
- Inhibitor
- inhibitor
- inhibit